PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
NCT02335892 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114
Last updated 2019-04-01
Summary
Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.
Conditions
- Relapsing Remitting Multiple Sclerosis
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-11-11
- Primary Completion
- 2017-02-01
- Completion
- 2017-02-01
Countries
- United Kingdom
Study Locations
More Related Trials
-
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT00289978 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
NCT01281657 ·Status: COMPLETED
-
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
NCT01755871 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
NCT01623596 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
NCT02232061 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
NCT01442194 ·Status: COMPLETED
-
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Fingolimod on Neurodegeneration
NCT02575365 ·Status: TERMINATED ·Phase: PHASE4
-
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
NCT01333501 ·Status: COMPLETED ·Phase: PHASE4
-
Fingolimod Real World Experience: the French Grand-Est Cohort
NCT02799199 ·Status: COMPLETED
-
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
NCT03345940 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
NCT04480853 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
NCT01498887 ·Status: COMPLETED ·Phase: PHASE4
-
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
NCT01910259 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Fingolimod Adherence on Outcomes
NCT05141669 ·Status: COMPLETED
-
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis
NCT01704183 ·Status: COMPLETED
-
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162 ·Status: COMPLETED
-
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00355134 ·Status: COMPLETED ·Phase: PHASE3
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
NCT01534182 ·Status: COMPLETED ·Phase: PHASE4
-
Teriflunomide Observational Effectiveness Study
NCT02490982 ·Status: COMPLETED
-
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT01310166 ·Status: COMPLETED ·Phase: PHASE4
-
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
NCT01981161 ·Status: COMPLETED
-
The MS-LINK™ Outcomes Study
NCT04735406 ·Status: COMPLETED
-
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
NCT01216072 ·Status: COMPLETED ·Phase: PHASE4